China Regenerative Medicine International
Wan Chai
About China Regenerative Medicine International
China Regenerative Medicine International manufacturing company for gene and stem cell products. China Regenerative Medicine International Limited (“CRMI”), listed on The Stock Exchange of Hong Kong Limited on 18 July 2001 (Stock Code: 8158.HK), is China’s first high-end new-technology enterprise principally engaged in research and development, production and sales of tissue engineering and regenerative medicine products. After unremitting efforts over the past decades, CRMI has evolved into a tissue engineering pioneer and has successfully industrialized regenerative medicine in the People’s Republic of China (P.R.C.), as well as accomplished the research and development and commercialization platform of tissue engineering. Headquartered in Hong Kong, CRMI has six modernized manufacturing facilities in Xi’an, Shenzhen, Suzhou, Tianjin and Hong Kong. Currently, CRMI has applied for more than 140 domestic and overseas patents and over 170 trademarks, and has undertaken various national pivotal projects. CRMI has presided over the development of the industry standard on two occasions, and has also received many significant scientific awards including the First Class Award of the National Science and Significant Scientific Technology Award. In 2014, CRMI collaborated with the University of Oxford in the UK to establish the‘CRMI Technology Centre at the University of Oxford’ where CRMI has designated it as its core R&D institution. Following the Rolls-Royce Group and Invensys Group, CRMI is the third enterprise to set up a technology and R & D centre with the University of Oxford. On 21st October 2015, CRMI has jointly entered into the memorandum of understanding with the University of Oxford and CCB International (Holdings) Ltd∩╝î during the State Visit to the United Kingdom by President Xi Jinping of the PRC. The memorandum depicts the establishment of a strategic platform for industrialization of biomedical research which is one of the 28 projects being selected during President Xi’s visit
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 251 – 500
- Estimated revenue: $100K – $500K
- Website: crmi.hk
- Phone: +85239668388
Social Profiles
Canonical: https://fsome.com/organization/china-regenerative-medicine-international-2795779 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.